Live
- Chandrayaan 3 created milestone, Chandrayaan 4 & 5 will follow: Jitendra Singh
- Chandrababu orders for High-Level Inquiry Into Atchutapuram blast incident
- How to Deal With Scabies?
- Flooding last year was due to peculiar rainfall patterns in Punjab, Himachal Pradesh: Study
- Successfully conduct Gram Sabhas on 23rd of this month
- Flood situation in Tripura worsens, death toll rises to 10, over 34,000 people in camps
- Mega Star Chiranjeevi arrived in Tirumala To Celebrate his birthday
- The Nifty Fifty Revisited: A Glimpse into India's Stock Market Phenomenon
- Odisha government felicitates Olympic Hockey medalists
- CPI(M) Leaders Meet Chief Minister Revanth Reddy
Dr Reddy's net zooms 30% to Rs 992 cr in Q2
Dr Reddy’s net zooms 30% to Rs 992 cr in Q2
Drug maker has posted a net profit of `762.3 crore for the corresponding period in FY21
Hyderabad: Drug major Dr Reddy's Laboratories on Friday reported a 30 per cent jump in its consolidated net profit to Rs 992 crore for the quarter ended September 30, 2021, on account of other income and robust sales in all markets.
The company had posted a net profit of Rs 762.3 crore for the corresponding period of the previous financial year, Dr Reddy's Laboratories said in a press release.Its consolidated revenue during July-September 2021 stood at Rs 5,763.2 crore. It was Rs 4,896.7 crore in the year-ago period, it added.
"I am pleased with the improvement in the financial performance across our businesses.
While we continue to strengthen our core businesses of genericsand APls (active pharmaceutical ingredients), we are also making investments in our long-term growth drivers and deeper innovation capabilities," Dr Reddy'sLaboratories co-Chairman and Managing Director G V Prasad said.Under the Covid-19 products basket, the drug maker launched Sputnik V vaccine, remdesivir, avigan and 2-deoxy-D-glucose (2-DG) till now.
